

Fabian Lohaus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9117253/publications.pdf>

Version: 2024-02-01

50
papers

1,941
citations

279487

23
h-index

253896

43
g-index

54
all docs

54
docs citations

54
times ranked

3563
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184
2	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
3	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.3	141
4	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.3	130
5	Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastasesâ€”A pooled analysis of the German working group â€œstereotactic radiotherapyâ€”. <i>Lung Cancer</i> , 2016, 97, 51-58.	0.9	128
6	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	3.2	127
7	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 485-491.	0.3	101
8	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
9	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
10	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3152-3163.	3.2	53
11	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	2.3	50
12	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	3.2	45
13	Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2019, 110, 11-20.	1.3	44
14	Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinomaâ€”a multicenter analysis of the German working group â€œStereotactic Radiotherapyâ€”. <i>Journal of Thoracic Disease</i> , 2017, 9, 4512-4522.	0.6	43
15	Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 511-520.	0.4	42
16	Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation. <i>Radiotherapy and Oncology</i> , 2019, 131, 127-134.	0.3	42
17	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019, 75, 548-551.	0.9	36
18	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. <i>Radiation Oncology</i> , 2018, 13, 90.	1.2	34

#	ARTICLE	IF	CITATIONS
19	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
20	Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT. <i>Clinical Lung Cancer</i> , 2019, 20, e667-e677.	1.1	33
21	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 40-47.	0.9	32
22	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-“staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	2.6	26
23	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. <i>Radiation Oncology</i> , 2017, 12, 190.	1.2	25
24	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.3	24
25	Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. <i>Frontiers in Oncology</i> , 2020, 10, 627379.	1.3	24
26	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 19-26.	0.9	22
27	Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the “TOaST”™ database. <i>Radiation Oncology</i> , 2021, 16, 4.	1.2	20
28	Bayesian Cure Rate Modeling of Local Tumor Control: Evaluation in Stereotactic Body Radiation Therapy for Pulmonary Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 841-849.	0.4	19
29	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19
30	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17
31	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	0.9	16
32	Comparison of GeneChip, nCounter, and Real-Time PCR-“Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	1.2	10
33	Evaluation of a deformable registration algorithm for subsequent lung computed tomography imaging during radiochemotherapy. <i>Medical Physics</i> , 2016, 43, 5028-5039.	1.6	9
34	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiation Oncology</i> , 2021, 16, 141.	1.2	9
35	Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 28-34.	0.3	8
36	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 135.	1.2	8

#	ARTICLE	IF	CITATIONS
37	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
38	Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis. <i>Cancers</i> , 2021, 13, 4780.	1.7	8
39	Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy. <i>British Journal of Radiology</i> , 2020, 93, 20190573.	1.0	7
40	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
41	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	0.9	6
42	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.3	5
43	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DTK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.3	5
44	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
45	Altered brain responses to emotional facial expressions in tinnitus patients. <i>Progress in Brain Research</i> , 2021, 262, 189-207.	0.9	2
46	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. <i>Annals of Translational Medicine</i> , 2015, 3, 255.	0.7	2
47	Tumor DNA Methylome derived Epigenetic Fingerprint Identifies HPV negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. <i>International Journal of Cancer</i> , 2021, 150, 603.	2.3	2
48	A Novel 2-Metogene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	1.7	2
49	Corrigendum to “HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DTK-ROG)” <i>Radiother. Oncol.</i> 113 (2014) 317–323. <i>Radiotherapy and Oncology</i> , 2015, 114, 419.	0.3	0
50	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus ZÄ¶phel, Steffen LÄ¶ck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? <i>Eur Urol</i> 2019;75:548–51. <i>European Urology</i> , 2019, 76, e103-e104.	0.9	0